Mallinckrodt Splurges Up To $410m On Three Hemostasis Drugs
This article was originally published in Scrip
Mallinckrodt PLC is buying three commercial-stage topical hemostasis drugs – Recothrom Thrombin topical (recombinant), PreveLeak Surgical Sealant, and Raplixa (Fibrin Sealant) from The Medicines Company for an initial payment of $175m that includes existing inventory. However, the value of the deal could rise by $235m subject to future milestone payments and the total could reach up to $410m.
Register for our free email digests: